Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...